EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

[1]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[2]  M. Barbacid,et al.  Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. , 2012, Bioorganic & medicinal chemistry letters.

[3]  A. Siriwardena,et al.  EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer , 2012, Pancreas.

[4]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[5]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[6]  D. Tuveson,et al.  Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma , 2012, The Journal of experimental medicine.

[7]  D. Tuveson,et al.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.

[8]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Vogt,et al.  PI3K and STAT3: a new alliance. , 2011, Cancer Discovery.

[10]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[11]  M. Barbacid,et al.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.

[12]  Jason Y. Park,et al.  Molecular signatures of pancreatic cancer. , 2011, Archives of pathology & laboratory medicine.

[13]  S. Akira,et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.

[14]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[15]  Altaf Mohammed,et al.  The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model , 2010, Cancer Prevention Research.

[16]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[17]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[18]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[19]  P. Majumder,et al.  Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. , 2009, Gastroenterology.

[20]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[21]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[22]  R. Schmid,et al.  Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. , 2007, Cancer cell.

[23]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[25]  T. Yeatman,et al.  EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. , 2006, The Journal of surgical research.

[26]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[27]  S. Leach,et al.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates , 2005, Development.

[28]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[29]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[30]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[31]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[32]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[33]  Ming-Sound Tsao,et al.  Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.

[34]  Ming-Sound Tsao,et al.  Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.

[35]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[36]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  H. Friess,et al.  Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. , 1994, Gut.

[38]  National Cancer Institute of Canada Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  P. Pour,et al.  Ductal metaplasia of human exocrine pancreas and its association with carcinoma. , 1985, Cancer research.